Patients Getting Trasylol More Likely to Die
By admin • May 15th, 2008 • Category: Heart Research
Print This Post
| 
Email This Post
A new Canadian study has confirmed that a Bayer anti-bleeding drug Trasylol, used during heart surgery, considerably increased the risk of dying compared to less-expensive alternatives.
Canadian research found that people given Trasylol (also known by its generic name aprotinin) face a 53% increased risk of death.
Bayer AG suspended marketing in the United States last November after preliminary results revealed problems with the medication.
Now, following release of the new results, the FDA said the manufacturer had begun removing any remaining stock of the drug from the U.S. market.
However, Bayer continues to sell Trasylol in some areas of the world. So far, Bayer said more than 80 lawsuits have been filed over Trasylol.
The results, published by the New England Journal of Medicine, show that for every 100 patients who received Trasylol during surgery, two more would die compared with a similar group receiving one of the other anti-bleeding agents.
Popularity: 70% [?]
